Stocktoria
JOHNSON & JOHNSON JNJ
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 1944-09-25
JOHNSON & JOHNSON statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Gross margin | 67.9% | 69.1% | 68.8% | 69.3% | 70.3% |
| Net margin | 28.5% | 15.8% | 41.3% | 22.4% | 26.5% |
| FCF margin | 20.9% | 22.3% | 21.4% | 21.5% | 25.1% |
| Return on assets | 13.5% | 7.8% | 21.0% | 9.6% | 11.5% |
| Return on equity | 32.9% | 19.7% | 51.1% | 23.4% | 28.2% |
| Debt / equity | 0.51× | 0.45× | 0.40× | 0.37× | 0.43× |
| Current ratio | 1.03 | 1.11 | 1.16 | 0.99 | 1.35 |
| Revenue growth | 6.0% | 4.3% | 6.5% | 1.6% | -4.7% |
Source: SEC EDGAR filings · CIK 0000200406 · as of 2025-12-28. Facts from filings plus Stocktoria's own computed scores — not investment advice.